New hope for older leukemia patients: drug may keep cancer away after transplant

NCT ID NCT03286530

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests whether the drug ruxolitinib can help prevent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) from coming back after a stem cell transplant. About 64 older adults in remission will take ruxolitinib as maintenance therapy. The goal is to see if it improves survival without causing graft-versus-host disease or relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ruxolitinib (Jakafi)
What this could lead to: If successful, this could offer a way to reduce the chance of leukemia returning after a stem cell transplant, helping older patients stay in remission longer.
What could go wrong: This is a phase 2 study with only 64 participants, so results are preliminary. Ruxolitinib may cause side effects like infections or blood count changes, and it may not prevent relapse for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA ACUTE MYELOID LEUKEMIA IN REMISSION ALLOGENEIC STEM CELL TRANSPLANTATION

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital

Boston, Massachusetts, 02115, United States
Medical College of Wisconsin

Wauwatosa, Wisconsin, 53226, United States
The Ohio State University

Columbus, Ohio, 43210, United States
Vanderbilt University

Nashville, Tennessee, 37235, United States
Washington University

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.